BiVictriX Therapeutics Limited

BiVictriX Therapeutics PLC is a UK-based drug discovery and development company which is focused on leveraging clinical experience to develop a new class of highly selective, next generation cancer therapeutics which exhibit superior potency, whilst significantly reducing treatment-related toxicities. The company utilises a first-in-class approach to generate a proprietary pipeline of Bi-Cygni ® Antibody Drug Conjugate therapeutics which are designed to selectively target cancer-specific antigen pairs, or "Bi-Cygni ® fingerprints", on tumour cells, which are largely absent from healthy cells.